International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM) - Takeaways - MDSpire

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

  • By

  • María-Victoria Mateos

  • Shaji Kumar

  • Meletios A. Dimopoulos

  • Verónica González-Calle

  • Efstathios Kastritis

  • Roman Hajek

  • Carlos Fernández De Larrea

  • Gareth J. Morgan

  • Giampaolo Merlini

  • Hartmut Goldschmidt

  • Catarina Geraldes

  • Alessandro Gozzetti

  • Charalampia Kyriakou

  • Laurent Garderet

  • Markus Hansson

  • Elena Zamagni

  • Dorotea Fantl

  • Xavier Leleu

  • Byung-Su Kim

  • Graça Esteves

  • Heinz Ludwig

  • Saad Usmani

  • Chang-Ki Min

  • Ming Qi

  • Jon Ukropec

  • Brendan M. Weiss

  • S. Vincent Rajkumar

  • Brian G. M. Durie

  • Jesús San-Miguel

  • October 16, 2020

  • 0 min

Share

  • 1

    Smoldering multiple myeloma (SMM) is a transitional stage between MGUS and active multiple myeloma, with a heterogeneous risk of progression.

  • 2

    The IMWG revised SMM criteria to identify high-risk patients with an 80% progression risk within 2 years, based on specific biomarkers.

  • 3

    Early treatment with lenalidomide has shown significant benefits in delaying progression to MM in high-risk SMM patients.

  • 4

    A new risk stratification model was developed to predict 2-year progression risk in SMM patients using M-protein, BMPCs, and sFLC ratios.

  • 5

    The study aimed to create an individualized risk scoring tool for SMM patients, enhancing the prediction of progression to MM.

Original Source(s)

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

  • by María-Victoria Mateos, Shaji Kumar, Meletios A. Dimopoulos, Verónica González-Calle, Efstathios Kastritis, Roman Hajek, Carlos Fernández De Larrea, Gareth J. Morgan, Giampaolo Merlini, Hartmut Goldschmidt, Catarina Geraldes, Alessandro Gozzetti, Charalampia Kyriakou, Laurent Garderet, Markus Hansson, Elena Zamagni, Dorotea Fantl, Xavier Leleu, Byung-Su Kim, Graça Esteves, Heinz Ludwig, Saad Usmani, Chang-Ki Min, Ming Qi, Jon Ukropec, Brendan M. Weiss, S. Vincent Rajkumar, Brian G. M. Durie, Jesús San-Miguel

  • October 16, 2020

Related Content

Bone marrow hemodilution assessment in multiple myeloma MRD by next generation flow cytometry - a mini review

Enterocolitis Associated with Immune Effector Cells Following BCMA-Targeted CAR T-Cell Therapy: Findings from a Multicenter Case Series

Evaluating Hypoalbuminemia as a Prognostic Indicator in Monoclonal Gammopathy of Undetermined Significance (MGUS) within Its Biological Framework